GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.

ABSTRACT:

Background

The interferon-induced protein known as guanylate-binding protein 2 (GBP2) has been linked to multiple different cancer types as an oncogenic gene. Although the role of GBP2 in cancer has been preliminarily explored, it is unclear how this protein interacts with tumor immunity in gastric cancer.

Methods

The expression, prognostic value, immune-correlations of GBP2 in gastric cancer was explored in multiple public and in-house cohorts. In addition, the pan-cancer analysis was performed to investigate the immunological role of GBP2 based on The Cancer Genome Atlas (TCGA) dataset, and the predictive value of GBP2 for immunotherapy was also examined in multiple public cohorts.

Results

GBP2 was highly expressed in tumor tissues and associated with poor prognosis

SUBMITTER: Wang Y 

PROVIDER: S-EPMC10544588 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature